1. Home
  2. XMAX vs PRTA Comparison

XMAX vs PRTA Comparison

Compare XMAX & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XMAX Inc. Common Stock

XMAX

XMAX Inc. Common Stock

N/A

Current Price

$8.78

Market Cap

529.8M

ML Signal

N/A

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$8.33

Market Cap

526.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XMAX
PRTA
Founded
N/A
2012
Country
United States
Ireland
Employees
22
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
529.8M
526.7M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
XMAX
PRTA
Price
$8.78
$8.33
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$19.00
AVG Volume (30 Days)
790.1K
541.5K
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.60
Revenue
N/A
$814,000.00
Revenue This Year
N/A
$1,111.38
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$13.53
Revenue Growth
N/A
N/A
52 Week Low
$8.10
$7.40
52 Week High
$9.31
$11.80

Technical Indicators

Market Signals
Indicator
XMAX
PRTA
Relative Strength Index (RSI) 59.50 38.36
Support Level $8.33 $8.12
Resistance Level $9.31 $10.29
Average True Range (ATR) 0.21 0.39
MACD 0.01 -0.04
Stochastic Oscillator 66.99 21.68

Price Performance

Historical Comparison
XMAX
PRTA

About XMAX XMAX Inc. Common Stock

XMax Inc is a designer and lifestyle furniture company. The company is a designer and distributor of contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. The company plans expansion into artificial intelligence (AI) while continuing to operate and develop its existing furniture business.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: